Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | HRH1 | P35367 | 5/20 | 0.59 |
| ▸ | CCR3 | P51677 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404411 | 0.94 | GPR119 (0.62) | GPR119HRH3HRH1CCR3ALDH1A1 | |
| SCHEMBL2774468 | 0.93 | GPR119 (0.71) | GPR119HRH3HRH1CCR3ALDH1A1 | |
| SCHEMBL5414999 | 0.88 | GPR119 (0.60) | GPR119HRH3HRH1CCR3CHEK2 | |
| SCHEMBL22278067 | 0.86 | GPR119 (0.62) | GPR119HRH3ALDH1A1CHEK2DPP4 | |
| SCHEMBL22278074 | 0.86 | GPR119 (0.62) | GPR119HRH3ALDH1A1CHEK2DPP4 | |
| SCHEMBL22278076 | 0.86 | GPR119 (0.62) | GPR119HRH3ALDH1A1CHEK2DPP4 | |
| SCHEMBL4720822 | 0.85 | HRH1 (0.62) | GPR119HRH3HRH1CCR3KCNH2 | |
| SCHEMBL16514077 | 0.83 | GPR119 (0.67) | GPR119HRH3ALDH1A1CHEK2DPP4 | |
| SCHEMBL15536283 | 0.83 | GPR119 (0.67) | GPR119HRH3ALDH1A1CHEK2 | |
| SCHEMBL3091210 | 0.83 | GPR119 (0.64) | GPR119HRH3ALDH1A1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493743-B1 | Substituted bipiperidine intermediates and derivatives thereof | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GPR119 1917/4885HRH3 29/4885HRH1 39/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GPR119 2100/4885HRH3 29/4885HRH1 38/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GPR119 1917/4885HRH3 29/4885HRH1 39/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GPR119 1917/4885HRH3 29/4885HRH1 39/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GPR119 2100/4885HRH3 29/4885HRH1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.